University of Aberdeen logo

AURA - Aberdeen University Research Archive

 

A Long-Term Study of Adverse Outcomes Associated With Oral Corticosteroid Use in COPD

Simple item page
dc.contributor.authorTse, Gary
dc.contributor.authorEmmanuel, Benjamin
dc.contributor.authorAriti, Cono
dc.contributor.authorBafadhel, Mona
dc.contributor.authorPapi, Alberto
dc.contributor.authorCarter, Victoria
dc.contributor.authorZhou, Jiandong
dc.contributor.authorSkinner, Derek
dc.contributor.authorXu, Xiao
dc.contributor.authorMüllerová, Hana
dc.contributor.authorPrice, David
dc.contributor.institutionUniversity of Aberdeen.Institute of Applied Health Sciencesen
dc.contributor.institutionUniversity of Aberdeen.Other Applied Health Sciencesen
dc.date.accessioned2023-11-15T13:55:01Z
dc.date.available2023-11-15T13:55:01Z
dc.date.issued2023-11-15
dc.descriptionAcknowledgments: The authors thank Hilda de Jong, PhD (the PHARMO Institute, Utrecht, the Netherlands) for her assistance in developing the study protocol. The authors also thank Sharen Lee (Cardiovascular Analytics Group, Hong Kong) for her technical assistance in generating the figures for the dose-dependent relationship between OCS dose and adverse outcomes. The authors also thank Colin Bonner, Linda Stotsky, Mario Marinazzo, and Philomena Britto, for their review of the plain language summary as people living with COPD; these individuals were compensated for their time. Medical writing support, under the guidance of the authors, was provided by Sara Cameron, MPhil, and Sarah Piggott, MChem, CMC Connect, a division of IPG Health Medical Communications, funded by AstraZeneca, in accordance with Good Publication Practice (GPP 2022) guidelines. Funding: This study was sponsored by AstraZeneca. All authors, including those employed by the funder of the study, were involved in the interpretation of data, and writing or revising the report, had final responsibility for the decision to submit for publication, and take responsibility for the integrity of the data and the accuracy of the data analysis.en
dc.description.statusPeer revieweden
dc.format.extent16
dc.format.extent6781784
dc.identifier282178507
dc.identifier454f6ec0-7c69-43e0-b5db-42d5a895e762
dc.identifier85177181573
dc.identifier38022830
dc.identifier.citationTse, G, Emmanuel, B, Ariti, C, Bafadhel, M, Papi, A, Carter, V, Zhou, J, Skinner, D, Xu, X, Müllerová, H & Price, D 2023, 'A Long-Term Study of Adverse Outcomes Associated With Oral Corticosteroid Use in COPD', International journal of chronic obstructive pulmonary disease , vol. 2023, no. 18, pp. 2565—2580. https://doi.org/10.2147/COPD.S433326en
dc.identifier.doi10.2147/COPD.S433326
dc.identifier.iss18en
dc.identifier.issn1176-9106
dc.identifier.urihttps://hdl.handle.net/2164/22203
dc.language.isoeng
dc.relation.ispartofInternational journal of chronic obstructive pulmonary diseaseen
dc.subjectSDG 3 - Good Health and Well-beingen
dc.subjectchronic obstructive pulmonary diseaseen
dc.subjectcohort studyen
dc.subjectCOPDen
dc.subjectcorticosteroidsen
dc.subjectobservationalen
dc.subjectPrimary Careen
dc.subjectR Medicineen
dc.subjectSupplementary Informationen
dc.subject.lccRen
dc.titleA Long-Term Study of Adverse Outcomes Associated With Oral Corticosteroid Use in COPDen
dc.typeJournal articleen

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
TSE_etal_IJCOPD_A_Long_Term_VoR.pdf
Size:
6.47 MB
Format:
Adobe Portable Document Format
Download

Collections

All research